+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder



Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder



Journal of Affective Disorders 137(1-3): 46-55



Serotonin transporter (SERT) binding is decreased in lymphocytes of depression patients and this decrease is partially reversed by antidepressant medication. However, recent evidence has shown that clustering of SERT on cell membranes is very important for receptor functionality. Alteration in SERT clustering on peripheral lymphocytes does not affect symptoms severity. At the most it is associated or predicts responsivity to treatment. We collected blood samples from 38 untreated and newly diagnosed depression patients at the time of diagnosis and after 8weeks of pharmacological treatment and of 38 control subjects. We used the Hamilton Scale to quantify the level of depression in patients both before and after pharmacological treatment. We then used immunocytochemistry to assess SERT protein clusters in lymphocyte blood samples. We found an increase in SERT cluster size, but not the number of SERT clusters, in naïve depression patients compared to control subjects. Based on the distribution of SERT cluster size we differentiated the naïve depression patients into two groups (D-I and D-II). Naïve D-I and D-II patients initially showed similar Hamilton scores. However, after pharmacological treatment the D-II patients showed a greater decrease in Hamilton scores than did the D-I patients, and they had an increase in the number of SERT clusters. The data should be replicated in a larger cohort of patients and with a proper clinical trial. We propose that SERT clustering in blood lymphocytes may be a putative biomarker for antidepressant efficacy in major depressive disorder.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036315606

Download citation: RISBibTeXText

PMID: 22257570

DOI: 10.1016/j.jad.2011.12.041


Related references

Comparative study of two protocols for quantitative image-analysis of serotonin transporter clustering in lymphocytes, a putative biomarker of therapeutic efficacy in major depression. Biomarker Research 5: 27, 2017

Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. Journal of Affective Disorders 163: 47-55, 2014

Therapeutic Antidepressant Potential of NONHSAG045500 in Regulating Serotonin Transporter in Major Depressive Disorder. Medical Science Monitor 24: 4465-4473, 2018

Patterns of Membrane Protein Clustering in Peripheral Lymphocytes as Predictors of Therapeutic Outcomes in Major Depressive Disorder. Frontiers in Pharmacology 10: 190, 2019

Serotonin transporter clustering in blood lymphocytes predicts the outcome on anhedonia scores in naïve depressive patients treated with antidepressant medication. Annals of General Psychiatry 14: 45, 2015

Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and Genomics 19(1): 67-76, 2009

Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology 193(4): 539-545, 2007

Low brain serotonin transporter binding in major depressive disorder. Psychiatry Research 202(2): 161-167, 2012

Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biological Psychiatry 62(8): 870-877, 2007

Serotonin transporter clustering in blood lymphocytes of reeler mice. Cardiovascular Psychiatry and Neurology 2010: 396282, 2010

Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. Journal of Psychiatry & Neuroscience 32(2): 86-102, 2007

Serotonin transporter polymorphism in Croatian patients with major depressive disorder. Psychiatria Danubina 18(1-2): 83-89, 2006

Hippocampal volume and serotonin transporter polymorphism in major depressive disorder. Acta Neuropsychiatrica 25(4): 206-214, 2013

The serotonin transporter gene locus in late-life major depressive disorder. American Journal of Geriatric Psychiatry 21(1): 67-77, 2014

Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biological Psychiatry 59(3): 224-229, 2005